News

Video

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Author(s):

Jorge Cortes, MD

Dr. Jorge E. Cortes provides a comprehensive overview of the 5-year follow-up results from the Phase 2 OPTIC study, showcasing the long-term efficacy, safety, and mutational analysis of ponatinib in patients with chronic-phase chronic myeloid leukemia, including outcomes related to dose modifications and mutation evolution.

Related Videos
LTE-1 ASPEN LTFU
Data from an Ongoing Phase 1/1b Study BGB-11417-101
Preliminary Results from the IMMagine-1 Trial
SNDX-5613
Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Glofit-GemOX
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia
Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
Related Content